Guardant Health (MIL:1GH) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1GH Guardant Health Inc MIL:1GH
43 GF Score
Price €138.30
GF Value €52.82
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Guardant Health Valuation Rank Related Terms

MIL:1GH
43GF Score
Guardant Health Inc MIL:1GH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Guardant Health (MIL:1GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €138.30 is trading 161.8% above its estimated GF Value™ of €52.82. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for MIL:1GH:

  • Valuation Rank:
  • GF Value™: €52.82 vs. price of €138.30 (161.8% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the MIL:1GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges GH:USA5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
43GF Score

Get the complete analysis for MIL:1GH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€138.30
Price
€52.82
GF Value